CompanyDTILNasdaqDurham, NC

Precision BioSciences, Inc.

Precision BioSciences develops in vivo gene editing therapies using its ARCUS platform for genetic and infectious diseases.

SEC EDGAR ClinicalTrials.gov precisionbiosciences.com

DEF 14ASep 4Latest SEC filing, period to Sep 4

Aug 24Latest story

August 2026

Precision BioSciences doses first patient in DMD gene-editing trial

Aug 24Clinical readoutPrecision BioSciences, Inc.

Precision BioSciences reports first biopsy evidence of cccDNA elimination in HBV trial

Aug 6Quarterly updatePrecision BioSciences, Inc.

July 2026

Precision BioSciences promotes CFO to COO, names new CFO effective August 1

Jul 27PeoplePrecision BioSciences, Inc.